Denali Therapeutics Inc. (DNLI)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Denali Therapeutics Inc. ("Denali" or the "Company") (NASDAQ: DNLI). Investors who purchased Denali securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Denali and certain of its officers and/or directors have violated federal securities laws.
On January 13, 2022, Denali issued a press release disclosing that on January 12, 2022, the company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) that the DNL919 (ATV:TREM2) Investigational New Drug (IND) application has been placed on clinical hold.” Denali further advised that “[t]he FDA indicated they will provide an official clinical hold letter to Denali in approximately 30 days.” On this news, Denali’s stock price fell $4.69 per share, or 12.17%, to close at $33.86 per share on January 13, 2022.
If you are aware of any facts relating to this investigation, or purchased Denali shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.